373 related articles for article (PubMed ID: 10463972)
1. Expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) and p53 tumor suppressor in dysplastic progression and adenocarcinoma in Barrett esophagus.
Hanas JS; Lerner MR; Lightfoot SA; Raczkowski C; Kastens DJ; Brackett DJ; Postier RG
Cancer; 1999 Sep; 86(5):756-63. PubMed ID: 10463972
[TBL] [Abstract][Full Text] [Related]
2. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
3. p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction.
Moskaluk CA; Heitmiller R; Zahurak M; Schwab D; Sidransky D; Hamilton SR
Hum Pathol; 1996 Nov; 27(11):1211-20. PubMed ID: 8912833
[TBL] [Abstract][Full Text] [Related]
4. Rab11a immunohistochemical analysis does not distinguish indefinite, low-, and high-grade dysplasia in Barrett esophagus.
Robert ME; Washington MK; Lee JR; Goldenring JR; Bronner MP; Goldblum JR; Greenson JK; Haber MM; Hart JA; Lamps LW; Lauwers GY; Lewin D; Lazenby AJ; Montgomery E; Crawford JM
Am J Clin Pathol; 2005 Oct; 124(4):519-27. PubMed ID: 16146818
[TBL] [Abstract][Full Text] [Related]
5. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus.
Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C
Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048
[TBL] [Abstract][Full Text] [Related]
6. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
Hermann B; Li Y; Ray MB; Wo JM; Martin RC
Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
[TBL] [Abstract][Full Text] [Related]
7. Immunohistological study of cell cycle-related factors, oncogene expression, and cell proliferation in adenocarcinoma developed in Barrett's esophagus.
Fujii T; Nakagawa S; Hanzawa M; Sueyoshi S; Fujita H; Shirouzu K; Yamana H
Oncol Rep; 2003; 10(2):427-31. PubMed ID: 12579284
[TBL] [Abstract][Full Text] [Related]
8. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
9. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
10. Relationship between dysplasia, p53 protein accumulation, DNA ploidy, and Glut1 overexpression in Barrett metaplasia.
Younes M; Lechago J; Chakraborty S; Ostrowski M; Bridges M; Meriano F; Solcher D; Barroso A; Whitman D; Schwartz J; Johnson C; Schmulen AC; Verm R; Balsaver A; Carlson N; Ertant A
Scand J Gastroenterol; 2000 Feb; 35(2):131-7. PubMed ID: 10720109
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical analysis of selected molecular markers in esophagus precancerous, adenocarcinoma and squamous cell carcinoma in Iranian subjects.
Allameh A; Rasmi Y; Nasseri-Moghaddam S; Tavangar SM; Sharifi R; Sadreddini M
Cancer Epidemiol; 2009 Jul; 33(1):79-84. PubMed ID: 19679052
[TBL] [Abstract][Full Text] [Related]
12. Population-based study reveals new risk-stratification biomarker panel for Barrett's esophagus.
Bird-Lieberman EL; Dunn JM; Coleman HG; Lao-Sirieix P; Oukrif D; Moore CE; Varghese S; Johnston BT; Arthur K; McManus DT; Novelli MR; O'Donovan M; Cardwell CR; Lovat LB; Murray LJ; Fitzgerald RC
Gastroenterology; 2012 Oct; 143(4):927-35.e3. PubMed ID: 22771507
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.
Wong NA; Mayer NJ; Anderson CE; McKenzie HC; Morris RG; Diebold J; Mayr D; Brock IW; Royds JA; Gilmour HM; Harrison DJ
Hum Pathol; 2003 Jun; 34(6):580-8. PubMed ID: 12827612
[TBL] [Abstract][Full Text] [Related]
14. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
15. The value of p53 and Ki67 as markers for tumour progression in the Barrett's dysplasia-carcinoma sequence.
Polkowski W; van Lanschot JJ; Ten Kate FJ; Baak JP; Tytgat GN; Obertop H; Voorn WJ; Offerhaus GJ
Surg Oncol; 1995 Jun; 4(3):163-71. PubMed ID: 7582189
[TBL] [Abstract][Full Text] [Related]
16. Suppression of apoptosis does not foster neoplastic growth in Barrett's esophagus.
Soslow RA; Remotti H; Baergen RN; Altorki NK
Mod Pathol; 1999 Mar; 12(3):239-50. PubMed ID: 10102608
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric DNA analysis and p53 protein expression show a good correlation with histologic findings in patients with Barrett's esophagus.
Giménez A; Minguela A; Parrilla P; Bermejo J; Pérez D; Molina J; García AM; Ortiz MA; Alvarez R; de Haro LM
Cancer; 1998 Aug; 83(4):641-51. PubMed ID: 9708926
[TBL] [Abstract][Full Text] [Related]
18. Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma.
Hayashi H; Miyamoto H; Ito T; Kameda Y; Nakamura N; Kubota Y; Kitamura H
Am J Pathol; 1997 Aug; 151(2):461-70. PubMed ID: 9250158
[TBL] [Abstract][Full Text] [Related]
19. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett's oesophagus.
Kastelein F; Biermann K; Steyerberg EW; Verheij J; Kalisvaart M; Looijenga LH; Stoop HA; Walter L; Kuipers EJ; Spaander MC; Bruno MJ;
Gut; 2013 Dec; 62(12):1676-83. PubMed ID: 23256952
[TBL] [Abstract][Full Text] [Related]
20. Topological analysis of p21WAF1/CIP1 expression in esophageal squamous dysplasia.
Shirakawa Y; Naomoto Y; Kimura M; Kawashima R; Yamatsuji T; Tamaki T; Hamada M; Haisa M; Tanaka N
Clin Cancer Res; 2000 Feb; 6(2):541-50. PubMed ID: 10690537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
